M
Maria Gavriatopoulou
Researcher at National and Kapodistrian University of Athens
Publications - 355
Citations - 6910
Maria Gavriatopoulou is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 36, co-authored 286 publications receiving 4265 citations. Previous affiliations of Maria Gavriatopoulou include Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma
Ajai Chari,Dan T Vogl,Maria Gavriatopoulou,Ajay K. Nooka,Andrew Yee,Carol Ann Huff,Philippe Moreau,David Dingli,Craig E. Cole,S. Lonial,Meletios A. Dimopoulos,A. Keith Stewart,Joshua Richter,Ravi Vij,Sascha Tuchman,Marc S Raab,Katja Weisel,Michel Delforge,Robert F Cornell,David Kaminetzky,James E. Hoffman,Luciano J. Costa,Terri L. Parker,Moshe Yair Levy,Martin Schreder,Nathalie Meuleman,Laurent Frenzel,Mohamad Mohty,Sylvain Choquet,Gary J. Schiller,Raymond L Comenzo,Monika Engelhardt,Thomas Illmer,Philip Vlummens,Chantal Doyen,Thierry Facon,Lionel Karlin,Aurore Perrot,Klaus Podar,Michael Kauffman,Sharon Shacham,Lingling Li,Shijie Tang,Carla Picklesimer,Jean-Richard Saint-Martin,Marsha Crochiere,Hua Chang,Samir Parekh,Yosef Landesman,Jatin Shah,Paul G. Richardson,Sundar Jagannath +51 more
TL;DR: Selinexor-dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies.
Journal ArticleDOI
Organ-specific manifestations of COVID-19 infection.
Maria Gavriatopoulou,Eleni Korompoki,Eleni Korompoki,Despina Fotiou,Ioannis Ntanasis-Stathopoulos,Theodora Psaltopoulou,Efstathios Kastritis,Evangelos Terpos,Meletios A. Dimopoulos +8 more
TL;DR: A comprehensive overview of the organ-specific systemic manifestations of COVID-19 is provided, showing that over a third of infected patients develop a broad spectrum of neurological symptoms affecting the central nervous system, peripheral nervous system and skeletal muscles, including anosmia and ageusia.
Journal ArticleDOI
Pathogenesis of bone disease in multiple myeloma: from bench to bedside.
TL;DR: An insight into the underlying pathogenesis of bone disease is provided to establish a positive feedback that sustains myeloma cell survival and continuous bone destruction, even when a plateau phase of the disease has been achieved.
Journal ArticleDOI
Emerging treatment strategies for COVID-19 infection.
Maria Gavriatopoulou,Ioannis Ntanasis-Stathopoulos,Eleni Korompoki,Eleni Korompoki,Despina Fotiou,Magdalini Migkou,Ioannis Georgios Tzanninis,Theodora Psaltopoulou,Efstathios Kastritis,Evangelos Terpos,Meletios A. Dimopoulos +10 more
TL;DR: The aim of this article is to describe the treatment strategies that have been used for COVID-19 patients and review all the available literature.
Journal ArticleDOI
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
Meletios A. Dimopoulos,Ramón García-Sanz,Maria Gavriatopoulou,Pierre Morel,Marie-Christine Kyrtsonis,Eurydiki Michalis,Zafiris Kartasis,Xavier Leleu,Giovanni Palladini,Alessandra Tedeschi,Dimitra Gika,Giampaolo Merlini,Efstathios Kastritis,Pieter Sonneveld +13 more
TL;DR: BDR is rapidly acting, well tolerated, and nonmyelotoxic, inducing durable responses in previously untreated patients with Waldenström macroglobulinemia in a phase 2 multicenter trial.